珈偉新能(300317.SZ):實控人一致行動人擬被動減持不超1%股份
格隆匯4月28日丨珈偉新能(300317.SZ)公佈,公司董事會近日收到公司實際控制人的一致行動人灝軒投資出具的《股份減持計劃告知函》,經過灝軒投資與中信證券華南股份有限公司(原名稱為“廣州證券股份有限公司”)協商,灝軒投資質押給中信證券的部分股票擬由中信證券進行減持。
減持方式為集中競價,減持期間為自該減持計劃公告之日起15個交易日後的90天內(減持區間為2020年5月25日至2020年8月23日),減持股份的總數不超過公司股份總數的1%,此次減持計劃的實施不會導致公司控制權發生變更。目前,灝軒投資直接持有公司股份8148.80萬股,佔公司總股本的9.89%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.